Safety And Efficacy Of Using A Convenient Dose Schedule Of Plerixafor Instead Of Standard Dose Schedule Of Plerixafor To Facilitate Outpatient Hematopoietic Stem Cell Collection In Multiple Myeloma (MM) Patients Scheduled To Undergo Autologous Hematopoietic Stem Cell Transplantation (HSCT).
Phase of Trial: Phase IV
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Plerixafor (Primary) ; Granulocyte colony-stimulating factors
- Indications Multiple myeloma; Stem cell mobilisation
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.